Alimera Improves Capital Structure, Strengthens Balance Sheet and Extends Term Loan Facility
March 27, 2023 08:00 ET
|
Alimera Sciences, Inc.
Repurchases Series A Preferred Stock, eliminating $24 million liquidation preference for approximately $938,000Completes $12 million private placement of preferred stock and warrants with conversion...
Alimera Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 31, 2023, and Provide Corporate Update
March 24, 2023 16:05 ET
|
Alimera Sciences, Inc.
ATLANTA, March 24, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Appoints Roger Sawhney, M.D. to Its Board of Directors
February 27, 2023 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Announces Submission of Marketing Authorization Application in Switzerland for ILUVIEN®
February 22, 2023 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial Officer
January 09, 2023 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners...
Alimera Sciences Announces Agreement to Extend Amortization Date and Interest-Only Period on Loan Agreement
December 08, 2022 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners...
Alimera Highlights Abstracts Regarding Consensus Among US Retina Specialists and Reduced Retinal Thickness Variability Leading to Improved Visual Outcomes Following ILUVIEN® Administration
November 29, 2022 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners...
Alimera Sciences Announces Third Quarter 2022 Financial Results
November 14, 2022 07:30 ET
|
Alimera Sciences, Inc.
Consolidated Net Product Revenue of $13.6 Million, up 11% vs. Third Quarter of 2021 Net Product Revenue Was Unfavorably Impacted by Approximately $800,000 in Foreign Currency Fluctuations ...
Alimera Sciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022, and Provide Corporate Update
November 02, 2022 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in the Czech Republic
November 01, 2022 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and...